Ken Griffin Dexcom Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$114.22 - $140.1 $43.7 Million - $53.6 Million	-382,400 Reduced 40.1%	571,100 $79.2 Million
Q4 2023 Feb 14, 2024	BUY	$75.49 - $124.16 $11.7 Million - $19.3 Million	155,100 Added 19.43%	953,500 $118 Million
Q3 2023 Nov 14, 2023	BUY	$86.06 - $137.93 $42.2 Million - $67.6 Million	490,200 Added 159.05%	798,400 $74.5 Million
Q2 2023 Aug 14, 2023	SELL	$112.47 - $130.98 $292,422 - $340,548	-2,600 Reduced 0.84%	308,200 $39.6 Million
Q1 2023 May 15, 2023	SELL	$104.0 - $122.92 $51.3 Million - $60.7 Million	-493,600 Reduced 61.36%	310,800 $36.1 Million

Q4 2022 Feb 14, 2023	SELL	$84.98 - $122.67 $3.65 Million - $5.27 Million	-43,000 Reduced 5.07%	804,400 $91.1 Million
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $16.9 Million - $20.9 Million	-221,800 Reduced 20.74%	847,400 $68.2 Million

1,123

352M

4.19M

4.54M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $43.8B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.